Stock Research: Astellas Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Astellas Pharma

TSE:4503 JP3942400007
83
  • Value
    25
  • Growth
    76
  • Safety
    Safety
    70
  • Combined
    67
  • Sentiment
    84
  • 360° View
    360° View
    83
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Astellas Pharma Inc. is a Japan-based pharmaceutical company focused on the research, development, manufacture, and sale of pharmaceutical products. The company operates in the pharmaceutical industry, with products including XTANDI, BETANIS, and MIRABETRIC. Astellas Pharma Inc. primarily operates in Japan. In the last fiscal year, the company had a market cap of $17,488 million, profits of $10,424 million, and revenue of $12,753 million, with 13,643 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 83 (better than 83% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Astellas Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Astellas Pharma. The consolidated Value Rank has an attractive rank of 70, which means that the share price of Astellas Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 70% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 76, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 84. But the company’s financing is risky with a Safety rank of 25. This means 75% of comparable companies have a safer financing structure than Astellas Pharma. ...read more

more
Index
TOPIX 100
Nikkei 225
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
70 70 66 67
Growth
76 49 19 89
Safety
Safety
25 10 39 39
Sentiment
84 16 6 14
360° View
360° View
83 21 12 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
31 30 50 65
Opinions Change
91 23 15 50
Pro Holdings
n/a 40 16 18
Market Pulse
47 26 9 17
Sentiment
84 16 6 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
70 70 66 67
Growth
76 49 19 89
Safety Safety
25 10 39 39
Combined
67 35 33 76
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
59 42 58 80
Price vs. Earnings (P/E)
64 74 59 50
Price vs. Book (P/B)
34 41 45 53
Dividend Yield
96 96 91 92
Value
70 70 66 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
44 18 58 47
Profit Growth
93 67 55 79
Capital Growth
47 71 4 54
Stock Returns
52 42 27 85
Growth
76 49 19 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
21 17 59 48
Refinancing
22 4 7 21
Liquidity
53 34 72 72
Safety Safety
25 10 39 39

Similar Stocks

Discover high‑ranked alternatives to Astellas Pharma and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Tokuyama

TSE:4043
Country: Japan
Industry: Specialty Chemicals
Size: Medium
Full Stock Analysis

Kumagai Gumi

TSE:1861
Country: Japan
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

Aeon Delight

TSE:9787
Country: Japan
Industry: Facility Services
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.